May. 19 at 7:13 PM
$INO They have about 37M warrants outstanding at 3 different walls.
$1.40 ,
$1.75 , and
$3.76 . The last offering won't last a full quarter. Another offering with mote warrants will be coming in about 2 months. Totally inept management with a CEO coming from a non-profit who was brought in to manage the burn. Advancing to commercialization is secondary and not her strong point. She also is a director who has no oversight to be fired for her poor leadership. She won't step down until a bankruptcy judge orders her to. Issues with the device are well documented. Not a good sign for a totally new platform relying on a device. CRL for the device is certain. In the clinical trial they switched the needle from side port on 11 patients to standard for 21 patients with no bridging data to support the change. The human factor is a big issue as well. FDA already said Accelerated Approval wasn't supported by the data. Standard Approval would require another trial. They're broke and desperate.
